GET DAILY SIGNALSSerina Therapeutics (SER): +565% Upside to a $10 Analyst Target
Key Takeaways
- The central $10 price target is the arithmetic mean of two verified analyst targets ($8.00 and $11.00, mean $9.50) rounded to a clean, reader-friendly level.
- With the stock recently near $1.50, reaching $10 would require roughly 565% upside — a very large move even for a clinical-stage biotechnology company.
- The analyst range is unusually wide, from $8.00 to $11.00, reflecting the binary, data-driven nature of early drug development.
- Strongest support comes from the SER-252 Phase 1 program in advanced Parkinson's disease and Serina's proprietary POZ polymer platform.
- Biggest risks are ongoing cash burn, potential dilution, clinical-trial failure, and the absence of any approved or revenue-generating products.
- For more detail, explore the ticker's Major News and Today's Price Move, as well as the Forecast and Earnings pages.
- Readers can also explore Trending AI Robots for AI-driven market ideas.
Analyst Price Targets and Consensus View
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company traded on NYSE American, focused on its POZ polymer platform for drug delivery, with a lead candidate, SER-252, aimed at advanced Parkinson's disease. It is a stock, not an ETF.
Only two current, individually attributable analyst targets were available for this thinly covered name. BTIG analyst Thomas Shrader reiterated a Buy rating with an $8.00 target in October 2026, while JonesTrading analyst Justin Walsh reiterated a Buy with an $11.00 target. The low-to-high range is therefore $8.00 to $11.00, and the calculated arithmetic mean is $9.50, which rounds to the $10 central target used here. Both analysts are effectively bullish, and the reasoning cited publicly points to SER-252's early efficacy signal and continued clinical progress.
The wide spread between $8.00 and $11.00 — more than 30% of the mean — underscores that these figures are high-uncertainty estimates, not guarantees. With only two contributors, this average is a thin base and should be read as directional context rather than a robust "analyst consensus."
Current Market Position and Path Toward the Target
The stock has recently traded near $1.50, within a 52-week range of roughly $1.14 to $4.26, giving the company a market capitalization of only about $36 million. To reach $10, shares would need to appreciate by approximately 565%, which is a very large move by any conventional standard. As a pre-revenue developer, Serina reports negative EPS and finances operations through cash reserves and equity raises.
A path toward $10 would almost certainly depend on clinical catalysts rather than near-term financials. Positive Phase 1 data for SER-252, progress toward a pivotal-stage trial, or a partnership or licensing deal could re-rate a micro-cap biotech sharply, though such moves remain speculative and are not assured. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Support a Move Toward the Target
The central investment thesis rests on SER-252 (POZ-apomorphine), a candidate intended to improve delivery of apomorphine for advanced Parkinson's disease. Analysts have cited an early efficacy signal in the Phase 1 program, and the broader POZ polymer technology is positioned as a non-immunogenic alternative to PEG-based delivery systems used in lipid nanoparticles. A meaningful unmet medical need in advanced Parkinson's disease, a low share count, and a strongly positive analyst rating profile are the principal supportive factors. Any favorable data readout or financing milestone could serve as a catalyst.
What Could Prevent the Target From Being Reached
The principal obstacles are execution and funding risk. Serina has reported quarterly net losses of roughly $6 million to $7 million with minimal revenue, meaning it will likely require additional capital, which could dilute existing shareholders. Clinical-stage biotechs face a high probability that a candidate fails to meet safety or efficacy endpoints. Competition in Parkinson's and delivery-platform technology is substantial, and the stock itself is volatile and thinly traded. A disappointing data readout, a delay, or adverse financing terms could push shares further from any elevated price objective.
Technical Levels and Market Structure
The most relevant technical landmarks are the 52-week low near $1.14 set in early November 2026 and the 52-week high around $4.26. The recent decline from roughly $1.92 to below $1.40 in a matter of sessions highlights the stock's volatility and thin liquidity. The $10 target sits far above any prior high, so there is no established support or resistance zone near it; it functions as a valuation aspiration tied to clinical success rather than a technical milestone.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, and the two targets cited here are consistent with a one-year outlook, though neither specifies a firm date publicly. The most important upcoming event is the next earnings report, currently expected around November 20, 2026. Investors should monitor SER-252 Phase 1 data updates, any guidance on a Phase 2 or pivotal trial, analyst target revisions, cash position and financing activity, and any partnership or licensing announcements.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals have become a regular part of how I scan for momentum shifts in names like this. The system monitors thousands of stocks and ETFs in real time, flagging Buy, Sell, or Hold signals based on technical behavior and market conditions. For a catalyst-driven micro-cap, these alerts can help surface changes that might otherwise slip past a purely fundamental review.
Final Assessment
The $10 central target for Serina Therapeutics is the rounded mean of two bullish analyst objectives ($8.00 and $11.00), implying roughly 565% upside from a price near $1.50. The thesis is entirely clinical: an early efficacy signal from SER-252 in advanced Parkinson's disease could justify a substantially higher valuation, but the company is pre-revenue, unprofitable, and likely to need further capital. With only two covering analysts and an unusually wide target range, this figure is best understood as a high-uncertainty, data-dependent aspiration rather than a forecast. Investors should watch upcoming earnings, SER-252 clinical updates, and financing developments before drawing conclusions.
Using Tickeron Tools for Biotech Research
In my own workflow, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check technical momentum alongside the fundamental story. The platform scans a broad universe of stocks and generates actionable signals that can highlight when sentiment or price action is starting to shift, which is especially useful for volatile names that move on clinical news. It is not a substitute for due diligence, but it adds a helpful layer of real-time context when I am evaluating catalyst-driven opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SER's RSI Indicator recovers from oversold territory
The RSI Oscillator for SER moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 26 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SER advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SER as a result. In 113 of 122 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SER turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 49 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 50-day moving average for SER moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SER entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.871) is normal, around the industry mean (3.498). P/E Ratio (-0.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. SER’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement